Idvynso uniquely offers a two-drug, tenofovir-free, non-INSTI single-tablet regimen intended for switch in stable, suppressed ...
FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard ...
INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results